These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
153 related items for PubMed ID: 22006369
1. Effect of histologic subtype on treatment and outcomes for esophageal cancer in the United States. Merkow RP, Bilimoria KY, McCarter MD, Chow WB, Gordon HS, Stewart AK, Ko CY, Bentrem DJ. Cancer; 2012 Jul 01; 118(13):3268-76. PubMed ID: 22006369 [Abstract] [Full Text] [Related]
3. Esophagectomy after concurrent chemoradiotherapy improves locoregional control in clinical stage II or III esophageal cancer patients. Liao Z, Zhang Z, Jin J, Ajani JA, Swisher SG, Stevens CW, Ho L, Smythe R, Vaporciyan AA, Putnam JB, Walsh GL, Roth JA, Yao JC, Allen PK, Cox JD, Komaki R. Int J Radiat Oncol Biol Phys; 2004 Dec 01; 60(5):1484-93. PubMed ID: 15590179 [Abstract] [Full Text] [Related]
7. Pretreatment T3-4 stage is an adverse prognostic factor in patients with esophageal squamous cell carcinoma who achieve pathological complete response following preoperative chemoradiotherapy. Chao YK, Chan SC, Liu YH, Chen HW, Wan YL, Chang HK, Fan KH, Liu HP. Ann Surg; 2009 Mar 01; 249(3):392-6. PubMed ID: 19247024 [Abstract] [Full Text] [Related]
8. Prognostic value of histology in resected lung cancer with emphasis on the relevance of the adenocarcinoma subtyping. Riquet M, Foucault C, Berna P, Assouad J, Dujon A, Danel C. Ann Thorac Surg; 2006 Jun 01; 81(6):1988-95. PubMed ID: 16731118 [Abstract] [Full Text] [Related]
9. Chemoradiotherapy before and after surgery for locally advanced esophageal cancer: a SEER-Medicare analysis. Hong JC, Murphy JD, Wang SJ, Koong AC, Chang DT. Ann Surg Oncol; 2013 Nov 01; 20(12):3999-4007. PubMed ID: 23800897 [Abstract] [Full Text] [Related]
10. Outcome of low-volume surgery for esophageal cancer in a high-volume referral center. Courrech Staal EF, van Coevorden F, Cats A, Aleman BM, van Velthuysen ML, Boot H, Peeters MJ, van Sandick JW. Ann Surg Oncol; 2009 Dec 01; 16(12):3219-26. PubMed ID: 19777184 [Abstract] [Full Text] [Related]
11. Use of multimodality neoadjuvant therapy for esophageal cancer in the United States: assessment of 987 hospitals. Merkow RP, Bilimoria KY, McCarter MD, Chow WB, Ko CY, Bentrem DJ. Ann Surg Oncol; 2012 Feb 01; 19(2):357-64. PubMed ID: 21769460 [Abstract] [Full Text] [Related]
12. Survival after esophageal resection for carcinoma: the importance of the histologic cell type. Alexiou C, Khan OA, Black E, Field ML, Onyeaka P, Beggs L, Duffy JP, Beggs DF. Ann Thorac Surg; 2006 Sep 01; 82(3):1073-7. PubMed ID: 16928541 [Abstract] [Full Text] [Related]
15. Prognostic impact of upper, middle, and lower third mucosal or submucosal infiltration in early esophageal cancer. Hölscher AH, Bollschweiler E, Schröder W, Metzger R, Gutschow C, Drebber U. Ann Surg; 2011 Nov 01; 254(5):802-7; discussion 807-8. PubMed ID: 22042472 [Abstract] [Full Text] [Related]
16. Treatment of esophageal cancer based on histology: a surveillance epidemiology and end results analysis. Chang DT, Chapman C, Shen J, Su Z, Koong AC. Am J Clin Oncol; 2009 Aug 01; 32(4):405-10. PubMed ID: 19415029 [Abstract] [Full Text] [Related]